Compliance News | May 20, 2019
On May 16, 2019, the U.S. House of Representatives passed the “Strengthening Health Care and Lowering Prescription Drug Costs Act” (HR 987). This bill is a package of seven different bills. Four bills would strengthen the Affordable Care Act (ACA) or roll back rules issued by the Trump Administration, while three bills aim to get generic prescription drugs into the market more quickly. This bill passed by a vote of 234-183, on a largely partisan basis, with five Republicans supporting the package. The package is unlikely to be considered by the Senate in its entirety, although the Senate may take action to address prescription drug prices.
The four ACA-related bills would:
The three generic drug bills would:
This action by the House follows on the heels of its passage May 9 of the “Protecting Americans with Preexisting Conditions Act of 2019” (HR 986). That bill prohibits HHS and Treasury from implementing the Trump Administration’s waiver guidance under Section 1332 of the ACA. Under that guidance, states can apply for broader waivers of certain ACA provisions than were permitted under guidance issued by the Obama Administration. This bill also passed the House on a largely partisan basis, with four Republicans voting for it.
Implications for Plan Sponsors
There are no immediate implications for plan sponsors of group health plans. The Senate is not likely to take up the ACA-related measures. However, the Senate Finance Committee has held a series of hearings on the price of prescription drugs, and could act on various measures aimed at lowering the cost of prescription drugs later this summer
This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.
Don't miss out. Join 16,000 others who already get the latest insights from Segal.